Journal article
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
I Pires da Silva, T Ahmed, ILM Reijers, AM Weppler, A Betof Warner, JR Patrinely, P Serra-Bellver, C Allayous, J Mangana, K Nguyen, L Zimmer, C Trojaniello, D Stout, M Lyle, O Klein, CL Gerard, O Michielin, A Haydon, PA Ascierto, MS Carlino Show all
Lancet Oncology | Published : 2021
Abstract
Background: Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. We aimed to determine the efficacy and safety of ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab) compared with ipilimumab monotherapy in patients who are resistant to anti-PD-(L)1 therapy (hereafter referred to as anti-PD-[L]1). Methods: This multicentre, retrospective, cohort study, was done at 15 melanoma centres in Australia, Europe, and the USA. We included adult patients (aged ≥18 years) with metastatic melanoma (unresectable stage III and IV..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
ABW is supported by the National Cancer Institute Cancer Center Core (P30-CA008748). AMM is supported by a Cancer Institute NSW Fellowship and Melanoma Institute Australia. GVL is supported by National Health and Medical Research Council Practitioner Fellowship and the University of Sydney Medical Foundation and Melanoma Institute Australia. Support for the study from the Ainsworth Foundation and Lady Fairfax Charitable Trust is gratefully acknowledged.